ABT secures CE Mark for dual glucose-ketone sensing technology

What happened: On May 27, Abbott Laboratories (ABT) secured a CE Mark for the world's first dual glucose-ketone sensing technology for diabetes, enabling simultaneous measurement of glucose and ketone levels. On June 3, ABT expanded its agreement with MiniMed to commercialize these sensors for integration with MiniMed's smart dosing systems. Separately, on June 16, ALZpath Inc. licensed its phosphorylated Tau 217 antibody to ABT for developing an in vitro diagnostic test for Alzheimer's disease.

Market impact: These developments drive ABT's growth in diabetes care and expand its reach into blood-based Alzheimer's disease testing. The diabetes market is valued at over $125 billion, and the Alzheimer's diagnostic market is expected to grow at a CAGR of 10.5% until 2028. ABT's stock, already a deep value pick, may see further upside as these opportunities materialize.

What to watch next: On July 22, ABT reports Q2 earnings, which will provide insights into the commercial progress of these new technologies. Additionally, watch for regulatory approvals in the U.S. and other major markets for the dual glucose-ketone sensing technology and the Alzheimer's diagnostic test. Lastly, monitor ABT's stock price reaction to these catalysts, as it may signal investor sentiment towards the company's growth prospects.